Han, Lijuan
Czech, Julia
Maurer, Angela
Brümmendorf, Tim H.
Chatain, Nicolas http://orcid.org/0000-0003-4485-3120
Koschmieder, Steffen
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (German Research Foundation) (KO2155/6-1)
José Carreras Leukämie-Stiftung (Deutsche José Carreras Leukämie-Stiftung) (DJCLS 16 R/2017)
Article History
Received: 3 June 2018
Revised: 10 July 2018
Accepted: 23 July 2018
First Online: 8 August 2018
Compliance with ethical standards
:
: THB has participated in advisory boards and satellite symposia for Ariad, Bristol-Myers Squibb, Merck, Novartis, and Pfizer (no personal honoraria); he has received research funding from Novartis and Pfizer and holds a patent on the combination of imatinib with hypusination inhibitors. SK is a member of the Advisory Boards of Pfizer, Incyte/Ariad, Novartis, AOP, BMS, and CTI; Honoraria: Novartis, BMS, Pfizer, Incyte/Ariad, and Shire; Scientific Research Support: Novartis Foundation, BMS, and Novartis; Others: Alexion. The remaining authors declare that they have no conflict of interest.